Drug & intervention
etoposide
RxCUI 4179
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Etoposide
Etoposide, sold under the brand name Vepesid among others, is a chemotherapy medication used for the treatments of a number of types of cancer including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer. It is also used for hemophagocytic lymphohistiocytosis. It is used by mouth or injection into a vein. Side effects are very common. They can include low blood cell counts, vomiting, loss of appetite, diarrhea, hair loss, and fever. Other severe side effects include allergic reactions and low blood pressure. Use during pregnancy will likely harm the fetus. Etoposide is in the topoisomerase inhibitor family of medication. It is believed to work by damaging DNA. Etoposide was approved for medical use in the United States in 1983. It is on the World Health Organization's List of Essential Medicines.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerNCT07739758 · 2026-08-18
RECRUITINGLow-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerNCT07583550 · 2026-07-20
RECRUITINGA Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)NCT07502300 · 2026-06-15
RECRUITINGA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)NCT07227597 · 2026-01-29
RECRUITINGA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174 · 2025-11-25
RECRUITINGDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · 2025-11-07
RECRUITINGUsing Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyNCT06769126 · 2025-11-06
RECRUITINGA Study of Ivonescimab in First-Line ES-SCLCNCT07245446 · 2025-10-29
RECRUITINGA Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung CancerNCT07381829 · 2025-10-27
RECRUITINGSintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerNCT07061535 · 2025-07-30
RECRUITINGA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25
RECRUITINGSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03
RECRUITINGPhase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLCNCT06769971 · 2025-02-01
RECRUITINGAtezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).NCT06663098 · 2025-01-24
RECRUITINGMaintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCNCT06497530 · 2024-12-01
RECRUITINGA Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaNCT06368817 · 2024-10-22
RECRUITINGAdebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain MetastasisNCT06418594 · 2024-10-10
RECRUITINGA Study on the Efficacy of Atezolizumab Combined with ChemotherapyNCT06780826 · 2024-08-28
RECRUITINGAdebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung CancerNCT06480864 · 2024-08-09
RECRUITINGTislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLCNCT06536868 · 2024-08-01
RECRUITINGA Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerNCT06483282 · 2024-06-21
RECRUITINGSupraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA StudyNCT06039371 · 2024-05-21
RECRUITINGPhase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body IrradiationNCT06110572 · 2024-04-24
RECRUITINGSafety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCNCT06217757 · 2024-04-18
RECRUITINGNeoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialNCT06256237 · 2024-04-01
RECRUITINGTeniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled StudyNCT07583511 · 2024-02-01
RECRUITINGIN10018 Combination Therapy in Treatment-naïve ES-SCLCNCT06030258 · 2023-10-30
RECRUITINGMOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerNCT05903092 · 2023-09-26
RECRUITINGTesting the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12
RECRUITINGDose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · 2023-02-22
RECRUITINGDurvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)NCT05068232 · 2022-08-19
RECRUITINGLamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerNCT04696575 · 2021-07-02
RECRUITINGA Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerNCT07802821 · 2026-10-15
NOT_YET_RECRUITINGA Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)NCT07843940 · 2026-10-05
NOT_YET_RECRUITINGBenmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNCT07538258 · 2026-04-20
NOT_YET_RECRUITINGA Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNCT07538271 · 2026-04-20
NOT_YET_RECRUITINGIparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerNCT07349225 · 2026-01-31
NOT_YET_RECRUITINGA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128 · 2025-08-18
ACTIVE_NOT_RECRUITINGToripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033NCT07097948 · 2025-08-01
NOT_YET_RECRUITINGBenmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNCT06931145 · 2025-04-15
NOT_YET_RECRUITINGConditions being studied
Lung Cancer57Small Cell Lung Cancer29Breast Cancer14Non-small Cell Lung Cancer14Small Cell Lung Carcinoma13Small-cell Lung Cancer13Extensive-Stage Small-Cell Lung Cancer12Extensive-Stage Small Cell Lung Cancer11Extensive Stage Lung Small Cell Carcinoma10Extensive Stage Small Cell Lung Cancer9Prostate Cancer9Stage IIIA Non-small Cell Lung Cancer7Small Cell Lung Cancer Extensive Stage6Unspecified Adult Solid Tumor, Protocol Specific6Stage III Lung Cancer AJCC v85Stage IIIB Non-small Cell Lung Cancer5Drug/Agent Toxicity by Tissue/Organ4Extensive Stage Small Cell Lung Carcinoma4SCLC4SCLC, Extensive Stage4
Research locations
ChicagoIllinois, United States45HoustonTexas, United States44New YorkNew York, United States44St LouisMissouri, United States41ClevelandOhio, United States39BaltimoreMaryland, United States37BostonMassachusetts, United States37CincinnatiOhio, United States34ColumbusOhio, United States31Los AngelesCalifornia, United States31OmahaNebraska, United States30PortlandOregon, United States30
Leading sponsors
National Cancer Institute (NCI)21Merck Sharp & Dohme LLC9AstraZeneca8Hoffmann-La Roche8SWOG Cancer Research Network8Alliance for Clinical Trials in Oncology7M.D. Anderson Cancer Center7Radiation Therapy Oncology Group7Bristol-Myers Squibb6Eli Lilly and Company5Shanghai Pulmonary Hospital, Shanghai, China5Sichuan University5University of Washington4AbbVie3Amgen3
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.